National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI)
Predicts survival in patients with diffuse large B-cell lymphoma (DLBCL).
This tool helps predict prognosis for patients diagnosed with diffuse large B-cell lymphoma. It is an update to the original IPI score and enhances risk stratification for those patients who receive rituximab treatment.
Management
Patients with advanced disease (e.g., Ann Arbor stage III–IV) and/or a poor prognosis should be considered for enrollment in a clinical trial, where possible.